Research programme: histone deacetylase inhibitors - EpiGen Pharmaceuticals
Alternative Names: HDAC inhibitorsLatest Information Update: 14 Sep 2023
Price :
$50 *
At a glance
- Originator University of Pennsylvania
- Developer EpiGen Pharmaceuticals
- Class Cardiovascular therapies
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myocardial reperfusion injury
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Myocardial reperfusion injury in USA (IV), prior to September 2023
- 28 Jan 2019 No recent reports of development identified for preclinical development in Myocardial reperfusion-injury in USA (IV)